Annual report pursuant to Section 13 and 15(d)

Reorganization and Recapitalization (Details)

v3.21.2
Reorganization and Recapitalization (Details)
12 Months Ended
Dec. 31, 2020
USD ($)
shares
Restructuring and Related Activities [Abstract]  
Reorganization description the Company issued an aggregate of 9,881,785 shares of common stock, and 1 share of preferred stock which is exchangeable into an aggregate of 1,664,083 shares of common stock at the option of the holders, to the former shareholders of CBR Pharma and 180 LP, in exchange for 100% of the outstanding equity and equity equivalents of CBR Pharma and 180 LP. Of the 9,881,785 shares of common stock issued in connection with the Reorganization, 2,694,053 shares were issued to a consultant were subject to redemption by 180 LP (the “Contingently Redeemable Shares”) for an aggregate redemption price of $4.00
Shares of common stock 3,965,059
Fair value of common stock equivalent 1,326,830
Research and development expense (in Dollars) | $ $ 588,349
Estimated tax rate 26.00%